Drug Profile
TQB 2618
Alternative Names: TQB-2618Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Nasopharyngeal cancer
- Phase I/II Lymphoma; Squamous cell cancer
- Phase I Acute myeloid leukaemia; Colorectal cancer; Liver cancer; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 13 Jan 2024 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06010901)
- 13 Jan 2024 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in China (Parenteral) (NCT06010901)
- 25 Aug 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase-I trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in China (Parenteral) (NCT06010901)